Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Anton M. Sholukh, Andrew Fioré-Gartland, Emily S. Ford, Maurine D. Miner, Yixuan J. Hou, Longping V. Tse, Hannah Kaiser, Haiying Zhu, Joyce Lu, Bhanupriya Madarampalli, Arnold Park, Florian A. Lempp, Russell St. Germain, Emily L. Bossard, Jia Jin Kee, Kurt Diem, Andrew B. Stuart, Peter B. Rupert, Chance Brock, Matthew Buerger, Margaret K. Doll, April K. Randhawa, Leonidas Stamatatos, Roland K. Strong, Colleen C. McLaughlin, Meei‐Li Huang, Keith R. Jerome, Ralph S. Baric, David C. Montefiori, Lawrence Corey
Abstract
data and showed similar correlation between assays and with IgG concentrations. The VSV pseudovirus assay and LV pseudovirus assay with HEK293T/hACE2 cells in low- and high-throughput versions were calibrated against the WHO SARS-CoV-2 IgG standard. High concordance between the outcomes of cell-based assays with live and pseudotyped virions enables valid cross-study comparison using these platforms.